Last reviewed · How we verify
PL2200 fasted
PL2200 fasted is a Small molecule drug developed by PLx Pharma. It is currently in Phase 1 development.
At a glance
| Generic name | PL2200 fasted |
|---|---|
| Sponsor | PLx Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PL2200 fasted CI brief — competitive landscape report
- PL2200 fasted updates RSS · CI watch RSS
- PLx Pharma portfolio CI
Frequently asked questions about PL2200 fasted
What is PL2200 fasted?
PL2200 fasted is a Small molecule drug developed by PLx Pharma.
Who makes PL2200 fasted?
PL2200 fasted is developed by PLx Pharma (see full PLx Pharma pipeline at /company/plx-pharma).
What development phase is PL2200 fasted in?
PL2200 fasted is in Phase 1.
Related
- Manufacturer: PLx Pharma — full pipeline
- Compare: PL2200 fasted vs similar drugs
- Pricing: PL2200 fasted cost, discount & access